TCV-309 chloride is a potent and selective platelet-activating factor (PAF) antagonist; it inhibits PAF-induced platelet aggregation in rabbits and humans and blocks [³H]PAF binding to rabbit platelet microsomes; it exhibits beneficial effects in anaphylactic shock; it selectively inhibits PAF-induced hypotension, hemoconcentration, and lethality in rats; it potently protects mice from PAF-induced and anaphylactic shock-induced death; it reverses both PAF-induced and endotoxin-induced hypotension in rats.